INTS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:00):
Our systems believe the stock currently is overvalued by -1.19% compare to its pairs and should correct downwards.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors...

Stats
Today's Volume	3 684
Average Volume	15 883
Market Cap	67.46M
EPS	$-0.340 ( Q1 \| 2024-05-09 )
Next earnings date	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.47 (Sector) 42.63 (Industry) 24.32
ATR14	$0.0520 (1.07%)

AADI -2.74%

ABCL -6.08%

ABCM 0.04%

ABEO -0.94%

ABIO -0.78%

ABOS -1.45%

ABSI -2.27%

ABUS 0.97%

ABVX 2.57%

ACAD -1.29%

ACER -17.95%

ACET -4.96%

ACGN 1.29%

ACHL -1.60%

ACHV 1.70%

ACIU -0.25%

ACLX -2.88%

ACRV 1.03%

ACST -2.34%

ACXP -4.89%

ADAG -0.33%

ADAP 7.70%

ADGI 0.87%

ADIL -5.22%

ADMA 3.31%

ADPT -0.55%

ADTX 14.49%

ADVM 1.60%

ADXN -12.26%

AEON -0.95%

AEZS 3.07%

AFMD -0.73%

AGEN -0.36%

AGIO 0.60%

AGLE 6.66%

AGTC 0.00%

AIKI 0.85%

AIMDW -13.88%

AKBA -2.51%

AKRO -1.28%

AKTX 15.23%

AKUS 0.00%

ALBO 0.00%

ALDX -1.81%

ALEC -2.64%

ALGS 5.43%

ALKS 1.20%

ALLK -12.02%

ALLO 0.00%

ALLR 6.44%

ALNA 3.16%

ALNY 0.13%

ALPN 0.02%

ALPX 0.00%

ALRN 1.08%

ALT 8.27%

ALVR 0.93%

ALXN 0.00%

ALXO -0.66%

ALZN 0.91%

AMRN -0.29%

AMTI -3.13%

ANAB -1.80%

ANEB -1.83%

ANGN 0.00%

ANIX 0.45%

ANL -6.05%

ANNX 3.06%

ANPC -3.15%

APGE -1.96%

APGN 8.48%

APGNW 30.65%

APLM 0.96%

APLS -5.40%

APLT -1.28%

APM -7.51%

APOP 0.38%

APRE -0.98%

APTO -1.51%

APTX 3.17%

APVO 9.15%

ARAV -13.39%

ARCT -2.83%

ARDS 19.76%

ARDX 2.16%

ARGX 0.97%

ARNA 0.00%

ARPO -0.90%

ARQT 2.80%

ARTL -3.57%

ARTLW 0.00%

ARVN -2.40%

ARWR 0.23%

ASLN 0.00%

ASMB -3.50%

ASND -1.76%

ATAI 1.50%

ATHA -5.28%

ATHE 0.00%

ATHX -33.50%

ATNF -7.98%

ATOS 0.84%

ATRA -1.65%

ATXI -2.86%

ATXS 1.65%

AUPH -3.85%

AURA -2.51%

AUTL -0.29%

AVBP -2.16%

AVEO 0.00%

AVIR 1.81%

AVRO -1.41%

AVTE 2.41%

AVTX 1.12%

AVXL -2.61%

AXLA 0.00%

AXSM 0.66%

AYLA 0.00%

AZRX 2.07%

BBI 2.17%

BBIO -0.51%

BCAB -1.46%

BCDA 0.67%

BCDAW 0.00%

BCEL 0.00%

BCLI 5.47%

BCRX 7.93%

BCTX -4.39%

BCTXW 17.17%

BCYC 0.25%

BDRX -0.23%

BDTX 0.86%

BEAM -1.62%

BFRA -2.91%

BGNE 1.56%

BIOR -4.56%

BIVI 4.00%

BLCM -6.68%

BLI -5.88%

BLPH -1.93%

BLRX -1.06%

BLTE 0.31%

BLU 0.03%

BLUE -0.90%

BMEA -1.78%

BMRN -0.24%

BNOX -10.04%

BNTC 3.92%

BNTX -1.90%

BOLD 8.27%

BOLT -2.41%

BPMC 1.30%

BPTH -3.00%

BPTS -13.47%

BRNS 2.14%

BRTX -2.46%

BTAI -8.59%

BTTX -15.97%

BTX 0.05%

BVXV 0.74%

BXRX 7.39%

BYSI 2.92%

CABA 4.41%

CADL 1.61%

CALA 0.00%

CALC 7.32%

CALT -0.62%

CAPR 1.47%

CARA 1.94%

CARM 9.87%

CASI -1.82%

CATB -6.97%

CBAY 0.03%

CBIO -2.65%

CBLI -7.31%

CBUS -5.89%

CCCC 4.98%

CCXI 0.00%

CDAK 0.00%

CDIO -1.82%

CDIOW 6.00%

CDMO -0.28%

CDMOP 0.04%

CDT -6.12%

CDTTW 72.08%

CDTX 0.84%

CDXC -1.47%

CDXS -3.55%

CELC 1.59%

CELU 1.92%

CELUW 1.32%

CERC -1.68%

CERE 1.13%

CERO -8.16%

CEROW 43.57%

CFRX -27.95%

CGEM -4.07%

CGEN 4.17%

CGON 0.48%

CGTX 0.60%

CHMA -6.00%

CHRS -6.94%

CINC 0.00%

CING 7.50%

CINGW 4.85%

CKPT -4.65%

CLBS -16.75%

CLDX 5.35%

CLGN 1.00%

CLLS 3.48%

CLNN 0.22%

CLNNW 44.05%

CLRB 2.00%

CLSD -4.62%

CLSN -0.68%

CLVS 0.00%

CMMB 5.00%

CMND -1.19%

CMPI 0.00%

CMPX -5.45%

CMRA 0.00%

CMRAW 33.33%

CMRX -0.80%

CNCE 0.00%

CNSP -10.13%

CNST 0.00%

CNTA -2.55%

CNTB -5.26%

CNTX -9.73%

COCP 3.00%

COEPW 0.00%

COGT 6.05%

CORT 0.55%

COYA 0.66%

CPRX 1.81%

CRBP 9.17%

CRBU -3.05%

CRDF -7.66%

CRGX -2.56%

CRIS -7.54%

CRNX 2.86%

CRSP -0.11%

CRTX 2.63%

CRVO -5.84%

CRVS 1.65%

CSBR -4.26%

CTCX 23.31%

CTIC 0.06%

CTMX 9.02%

CTNM 19.25%

CTXR -6.92%

CUE -17.74%

CVAC -2.06%

CVKD -1.15%

CWBR 0.00%

CYAD -12.96%

CYCC 0.00%

CYCCP -11.68%

CYCN 0.88%

CYT -2.27%

CYTK 0.96%

CYTO 9.91%

DARE -6.03%

DAWN -1.45%

DBTX -0.81%

DBVT 2.20%

DFFN 10.28%

DICE 0.06%

DMAC 0.00%

DNLI -5.21%

DNTH 11.55%

DOMH 4.81%

DRMA -5.37%

DRMAW 7.69%

DRNA 0.00%

DRTS 0.79%

DRTSW 19.05%

DRUG -2.77%

DSGN -2.99%

DTIL 1.64%

DYAI 3.38%

EARS -1.77%

EDIT -1.28%

EDSA 2.09%

EFTR -8.00%

EFTRW -41.67%

EIGR -9.21%

ELAB 0.07%

ELDN -4.92%

ELEV 5.93%

ELOX 1.45%

ELTX -8.03%

ELVN -2.87%

ELYM -0.84%

ENGN -4.03%

ENGNW -2.88%

ENLV -2.82%

ENOB 1.79%

ENSC -1.23%

ENTA 0.77%

ENTO -11.11%

ENTX -4.35%

ENVB -5.90%

EPIX -2.66%

EPRX 2.38%

EPZM 0.00%

EQ -2.21%

EQRX -2.09%

EQRXW 0.00%

ERAS 3.39%

ERNA 4.14%

ERYP 1.30%

ESLA 4.76%

ESLAW 0.00%

ETNB -3.12%

ETON 3.34%

ETTX 0.00%

EVAX 0.70%

EVGN -0.91%

EVLO 39 899.32%

EWTX 7.61%

EXAI 0.98%

EXEL -0.98%

EYEG -0.51%

EYEN 14.27%

EYPT -4.48%

FATE -0.61%

FBIO -1.17%

FBIOP 0.70%

FBLG -19.84%

FBRX 1.68%

FDMT 1.67%

FENC 2.62%

FGEN -13.69%

FHTX 1.57%

FIXX 0.77%

FMTX 0.00%

FNCH -10.95%

FOLD -1.21%

FREQ 4.76%

FRLN 0.15%

FRTX -4.21%

FSTX 0.00%

FTRE 2.23%

FULC 1.77%

FUSN 0.00%

FWBI 4.59%

FWP 0.00%

GALT 3.98%

GANX -12.50%

GBIO -8.87%

GBT 0.01%

GDTC -0.99%

GERN 2.36%

GHRS 0.77%

GLMD -1.01%

GLPG 0.93%

GLSI -2.84%

GLTO -1.73%

GLUE 5.35%

GLYC 5.15%

GMAB -1.11%

GMDA -18.25%

GMTX 0.00%

GNCA -85.71%

GNFT 10.80%

GNLX -5.64%

GNPX 2.39%

GNTA -0.87%

GOSS 5.18%

GOVX 2.98%

GOVXW -10.37%

GPCR 1.86%

GRAY -10.80%

GRCL 0.05%

GRNA -0.03%

GRNAW 8.91%

GRPH -2.75%

GRTS -6.13%

GRTX -8.63%

GTHX 8.33%

GUTS 4.45%

GXGXW 41.67%

GYRE 0.92%

HALO -0.65%

HARP 0.09%

HCWB 0.46%

HEPA -0.93%

HGEN -84.62%

HILS 5.66%

HLVX -0.28%

HOOK 6.17%

HOTH -1.12%

HOWL -3.69%

HRMY 0.83%

HRTX -0.86%

HSTO 0.00%

HUMA 11.88%

HUMAW 22.30%

IBRX -0.79%

ICCC -8.04%

ICPT 0.21%

ICU 23.06%

ICUCW 13.26%

ICVX -0.91%

IDRA -23.04%

IDYA 2.31%

IFRX -1.72%

IGMS -1.16%

IKNA 0.00%

IKT -5.34%

IMAB -2.99%

IMCR 7.49%

IMGN 0.02%

IMGO 0.00%

IMMP 0.00%

IMMX 7.07%

IMNM 0.83%

IMNN 8.62%

IMPL -27.27%

IMRA 15.96%

IMRN -9.26%

IMRX -8.59%

IMTX 3.27%

IMTXW 27.41%

IMUX 0.90%

IMV 0.00%

IMVT 4.20%

INAB -3.95%

INBX -3.03%

INCY 0.41%

INDP 4.25%

INFI -52.38%

INKT -3.51%

INM -5.24%

INMB -4.54%

INO 6.56%

INSM -0.99%

INTS 0.41%

INVA 0.61%

INZY -1.12%

IOBT -4.27%

IONS -1.15%

IOVA 0.50%

IPA -3.71%

IPHA 7.22%

IPSC -5.49%

IRON 3.11%

ISEE 0.38%

ITOS 1.15%

ITRM -5.60%

IVA -1.19%

IVVD 9.09%

JAGX -2.79%

JANX -0.41%

JAZZ -0.24%

JNCE 0.00%

JSPR 1.94%

JSPRW 5.15%

JUNS 0.00%

JUNSW 0.00%

KA 4.20%

KALV 0.93%

KDNY 0.22%

KMPH -0.34%

KNSA -3.59%

KNTE -0.38%

KOD 0.85%

KPRX 3.57%

KPTI -6.01%

KRBP -1.83%

KRON -9.68%

KROS -4.22%

KRRO -0.06%

KRTX 0.03%

KRYS -0.75%

KTRA 10.14%

KTTA 0.38%

KTTAW 1.83%

KURA 2.96%

KYMR 3.69%

KYTX 4.13%

KZIA -4.91%

KZR -2.73%

LABP 0.57%

LBPH 14.39%

LBPS 0.00%

LBPSW 14.81%

LEGN 3.91%

LENZ 2.31%

LEXX -0.72%

LEXXW 23.90%

LGND 0.70%

LGNDV 0.00%

LGVN -2.48%

LIAN -8.28%

LIFE 2.70%

LIPO -3.41%

LIXT -0.38%

LIXTW -3.71%

LJPC -0.32%

LMNL 0.12%

LOGC -3.15%

LPCN -6.31%

LPTX -4.59%

LQDA 0.33%

LRMR 13.66%

LSTA 2.31%

LTRN -3.21%

LUMO -2.46%

LVTX 3.89%

LXEO -2.68%

LXRX -0.30%

LYEL 8.97%

LYRA 7.30%

MACK 0.10%

MBIO 2.41%

MBRX -1.15%

MCRB -0.25%

MDGL -0.30%

MDNA -13.16%

MDWD -0.84%

MDXG -3.32%

MEIP -2.06%

MESO -0.44%

MGNX 1.18%

MGTA -7.74%

MGTX -2.61%

MGX 8.33%

MIRM -0.09%

MIRO 0.59%

MIST 0.75%

MITO 0.00%

MLEC -0.88%

MLECW -31.50%

MLND -5.36%

MLTX -4.94%

MLYS 4.02%

MNKD -2.49%

MNMD -1.94%

MNOV 0.00%

MNPR -0.88%

MOLN 2.80%

MOR -0.22%

MORF -4.46%

MREO 0.83%

MRKR -0.74%

MRNA -2.36%

MRNS 9.40%

MRSN -1.99%

MRTX -0.17%

MRUS -7.98%

MRVI -3.07%

MTCR -1.29%

MTEM 2.61%

MTP -18.50%

MURA -0.96%

MYMD 0.00%

NAMS 7.13%

NAMSW -4.76%

NAUT -2.99%

NBRV 0.71%

NBSE -1.56%

NBTX 7.00%

NCNA 7.36%

NERV -0.86%

NEXI -6.90%

NGM -1.28%

NGNE 11.62%

NKGN 0.00%

NKGNW -12.00%

NKTR -1.61%

NKTX -1.02%

NLSP -9.50%

NLSPW 26.58%

NMRA 1.12%

NMTR -42.97%

NOVN -24.84%

NRBO -6.20%

NRIX 0.19%

NRSN -3.57%

NRSNW -2.91%

NRXP 5.74%

NRXPW 41.43%

NRXS 1.44%

NTBL -6.12%

NTEC -12.45%

NTHI 0.00%

NTLA 0.40%

NTRBW 74.65%

NUVL -0.46%

NVAX 0.55%

NVCT -2.37%

NVIV -34.28%

NXTC -5.66%

NYMX -0.05%

OABI -0.27%

OABIW -9.28%

OBIO -12.64%

OBSV 0.00%

OCEA -3.28%

OCGN 4.84%

OCS -0.50%

OCUL -2.63%

OCUP 3.92%

ODT -4.27%

OKYO 1.64%

OLMA 2.96%

OMER -2.71%

OMGA 8.70%

ONCO -6.10%

ONCR -3.08%

ONCS 31.87%

ONCT -7.70%

ONCY 0.53%

ONTX -0.47%

ONVO -0.34%

OPNT 0.00%

OPT -0.99%

ORGS 8.13%

ORIC 8.06%

ORMP -0.39%

ORPH 0.00%

ORTX 0.30%

OSMT -1.77%

OTIC -92.64%

OTLK 0.41%

OVID 12.09%

OYST 0.00%

PALI -5.29%

PASG 11.43%

PBLA -10.00%

PBM 6.33%

PBYI 0.61%

PCSA -7.11%

PCVX 1.89%

PDSB 3.41%

PEPG 12.22%

PGEN -1.90%

PHAR -4.62%

PHAS 0.00%

PHAT 4.95%

PHIO -3.88%

PHIOW 36.47%

PHVS -0.59%

PHXM -5.20%

PIRS -1.82%

PKBO 0.00%

PKBOW 999 900.00%

PLRX 1.02%

PLUR -0.43%

PMN 6.67%

PMVP -2.47%

PNT 0.16%

PPBT -13.47%

PRAX -0.41%

PRDS 0.93%

PRLD -1.05%

PROG -3.47%

PROK 1.63%

PRQR -0.60%

PRTA -0.78%

PRTC 3.68%

PRTG -7.63%

PRTK 1.83%

PRVB 0.00%

PSTI -2.91%

PSTV 2.04%

PSTX 3.08%

PTCT 1.93%

PTE -0.82%

PTGX 1.59%

PTIXW -48.41%

PULM 1.55%

PXMD -1.27%

PYPD -0.24%

PYXS -3.32%

QLGN -3.77%

QNCX -3.33%

QNRX 1.75%

QSI -11.01%

QSIAW 4.08%

QTTB 5.74%

QURE -0.78%

RAIN -1.63%

RANI 0.53%

RAPT -5.57%

RARE 0.05%

RCKT -4.04%

REGN 0.57%

RENB -10.86%

REPL 4.00%

RETA 0.02%

REUN -0.89%

REVB -1.58%

REVBU 3.46%

REVBW 0.00%

RGLS 6.44%

RGNX -5.38%

RIGL 2.31%

RLAY -1.84%

RLMD 2.33%

RLYB 1.49%

RNA 1.05%

RNAC -10.14%

RNAZ -4.54%

RNXT 1.77%

ROIV 2.46%

ROIVW 4.56%

RPHM 2.65%

RPRX -0.68%

RPTX 0.91%

RUBY 2.70%

RVLP -32.05%

RVMD 0.00%

RVMDW -1.40%

RVNC 0.00%

RVPH -7.03%

RVPHW 4.88%

RXDX 0.09%

RXRX -0.53%

RYTM 3.92%

RYZB 0.02%

RZLT 0.23%

SABS -1.94%

SABSW 54.57%

SAGE 1.57%

SANA 0.18%

SAVA -1.70%

SAVAW 0.00%

SBBP 1.52%

SBTX 1.03%

SCNI 3.16%

SCPH -0.69%

SCPS 0.00%

SEEL 3.69%

SEER 0.60%

SELB -8.00%

SESN 7.29%

SGEN -0.07%

SGMO -7.90%

SGMT -7.60%

SGTX -2.56%

SIOX 22.63%

SLDB 10.58%

SLGL -4.21%

SLN -1.37%

SLNO 3.65%

SLRX -7.92%

SLS -0.84%

SMMT 4.36%

SNDX 4.87%

SNGX -4.26%

SNPX 1.97%

SONN -0.80%

SPPI -0.49%

SPRB 2.55%

SPRC -5.98%

SPRO -1.54%

SRNE -20.00%

SRPT -0.79%

SRRA 0.00%

SRRK -2.40%

SRZN -2.28%

STAB 0.00%

STOK 2.66%

STRO 4.10%

STSA 0.00%

STTK 3.37%

SURF -0.93%

SVRA 15.14%

SWTX 2.28%

SYBX -0.67%

SYRS -4.46%

TALS -0.73%

TARA 0.48%

TARS 3.90%

TBPH 0.47%

TCBP 1.76%

TCDA 0.00%

TCON -30.63%

TCRR 0.00%

TCRT -6.87%

TCRX 1.37%

TECH -0.06%

TENX -1.32%

TERN 0.59%

TFFP 7.23%

TGTX 2.02%

THRX 0.12%

TIL 0.10%

TLC 0.00%

TLSA -3.63%

TNGX 4.90%

TNXP 4.96%

TNYA 8.71%

TPST -2.28%

TRDA 0.49%

TRVI -3.02%

TRVN -3.81%

TSHA 0.89%

TSVT 5.19%

TTNP -0.18%

TVTX 0.73%

TYRA 8.07%

UBX -1.48%

UNCY 7.76%

URGN -1.79%

UTHR 0.14%

VACC 11.36%

VALN -3.27%

VAXX 20.24%

VBIV 4.85%

VBLT -8.77%

VCEL -1.85%

VCNX -0.15%

VCYT -1.57%

VERA 0.30%

VERU 4.45%

VERV 2.05%

VIGL 9.25%

VINC -6.26%

VIR 2.25%

VIRI 3.26%

VIRX -6.20%

VKTX 4.36%

VLON -13.04%

VNDA -1.24%

VOR -1.07%

VRCA 9.05%

VRDN 1.54%

VRNA 7.26%

VRPX -1.59%

VRTX 0.54%

VSTM 9.06%

VTGN 2.59%

VTVT -0.42%

VTYX -2.16%

VXRT 3.19%

VYGR -0.63%

VYNE -2.54%

VYNT 7.78%

WINT 0.00%

WVE 4.91%

XBIO -0.48%

XBIT 7.98%

XCUR -3.93%

XENE -3.33%

XERS -3.56%

XFOR 1.62%

XLO -2.49%

XLRN 0.00%

XNCR 0.48%

XOMA 5.11%

XOMAO 0.20%

XOMAP 1.98%

XRTX -1.06%

YMAB -2.07%

ZGNX 0.00%

ZIOP -0.88%

ZLAB -0.23%

ZNTL 2.45%

ZSAN 0.00%

Insider Trading

Date	Person	Action	Amount	type
2024-06-05	Wesolowski John M	Sell	1 000	Stock Option (right to buy Common Stock)
2024-06-05	Wesolowski John M	Buy	1 000	Common Stock, $0.0001 Par Value
2024-05-14	Dubin Thomas I H	Buy	50 000	Stock Option (right to buy Common Stock)
2024-05-14	Dubin Thomas I H	Buy	0
2024-03-06	Wesolowski John M	Buy	25 000	Stock Option (right to buy Common Stock)

INSIDER POWER
61.04
Last 26 transactions
Buy: 854 379 \| Sell: 332 500

Correlation (AI algo v.1.1b): Overvalued: -1.19% $4.92 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Intensity Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intensity Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2023
Revenue:	$0
Gross Profit:	$-147 000 (0.00 %)
EPS:	$-1.220

FY	2022
Revenue:	$0
Gross Profit:	$-179 037 (0.00 %)
EPS:	$-0.570

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.439

Financial Reports:

No articles found.

Intensity Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Intensity Therapeutics,

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company\'s lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.